Suppr超能文献

基于吡唑的p38激酶抑制剂的合成、晶体结构及活性

Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.

作者信息

Graneto Matthew J, Kurumbail Ravi G, Vazquez Michael L, Shieh Huey-Sheng, Pawlitz Jennifer L, Williams Jennifer M, Stallings William C, Geng Lifeng, Naraian Ashok S, Koszyk Francis J, Stealey Michael A, Xu Xiangdong D, Weier Richard M, Hanson Gunnar J, Mourey Robert J, Compton Robert P, Mnich Stephen J, Anderson Gary D, Monahan Joseph B, Devraj Rajesh

机构信息

Pfizer Global Research & Development, St. Louis Laboratories, 700 Chesterfield Village Parkway, Chesterfield, Missouri 63107, USA.

出版信息

J Med Chem. 2007 Nov 15;50(23):5712-9. doi: 10.1021/jm0611915. Epub 2007 Oct 19.

Abstract

A series of pyrazole inhibitors of p38 mitogen-activated protein (MAP) kinase were designed using a binding model based on the crystal structure of 1 (SC-102) bound to p38 enzyme. New chemistry using dithietanes was developed to assemble nitrogen-linked substituents at the 5-position of pyrazoles. Calculated log D was used in tandem with structure-based design to guide medicinal chemistry strategy and improve the in vivo activity of a series of molecules. The crystal structure of an optimized inhibitor, 4 (SC-806), in complex with p38 enzyme was obtained to confirm the hypothesis that the addition of a basic nitrogen to the molecule induces an interaction with Asp112 of p38 alpha. A compound identified from this series was efficacious in an animal model of rheumatic disease.

摘要

基于与p38酶结合的1(SC - 102)的晶体结构构建结合模型,设计了一系列p38丝裂原活化蛋白(MAP)激酶的吡唑类抑制剂。开发了使用二硫杂环丁烷的新化学方法,以在吡唑的5位组装氮连接的取代基。计算得到的log D与基于结构的设计一起用于指导药物化学策略,并提高一系列分子的体内活性。获得了优化抑制剂4(SC - 806)与p38酶复合物的晶体结构,以证实向分子中添加碱性氮会诱导与p38α的Asp112相互作用这一假设。从该系列中鉴定出的一种化合物在风湿性疾病动物模型中有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验